MoonLake Immunotherapeutics (NasdaqCM: MLTX)
Health Care · Biotechnology · CH
$10.82
+2.27% today · +15.4% 1Y
MoonLake Immunotherapeutics (NasdaqCM: MLTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $920.85M and employs 130 people.
Over the last twelve months the share price has gained 15.4%, trading between 8.80 and 23.29.
Tweenvest scores MoonLake Immunotherapeutics across four factors: quality 37/100, value 35/100. Its strongest factor is quality.
MLTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $920.85M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.81
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $23.29
- 52-week low
- $8.80
- Avg volume (3M)
- —
- Shares outstanding
- 85.11M
- Employees
- 130
- Next earnings
- —
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
- ISIN
- KY61559X1045
- Founded
- 2021
- Listed since
- Oct 20, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kura Oncology, Inc.NasdaqGS: KURA | $942.98M | $10.60 | +0.76% |
| Ascletis Pharma Inc.SEHK: 1672 | $936.85M | HK$6.96 | -14.23% |
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $932.34M | ₩25,350.00 | -12.13% |
| LongBio Pharma (Suzhou) Co., Ltd.SEHK: 1779 | $926.52M | HK$98.00 | -3.64% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $916.81M | $49.08 | +0.74% |
| Jade Biosciences, Inc.NasdaqCM: JBIO | $915.17M | $14.39 | +1.91% |
| Odyssey Therapeutics, Inc.NasdaqCM: ODTX | $910.45M | $19.00 | -8.32% |
| Alphamab OncologySEHK: 9966 | $907.71M | HK$7.36 | -11.44% |
Figures last refreshed Oct 11, 2026.